Ascentage Pharma updates Hong Kong business address

Ascentage Pharma Group International has changed its principal place of business in Hong Kong.

Accepted by SEC EDGAR 04/01/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ascentage Pharma Group International has changed its principal place of business in Hong Kong. Effective April 1, 2026, the address is now Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong.

The change is reported on a Form 6-K, which furnishes the related Hong Kong announcement and is signed by Chief Executive Officer Dr. Dajun Yang.

Key Figures

Effective date of Hong Kong address change: April 1, 2026

1 metrics

Effective date of Hong Kong address change April 1, 2026 Change of principal place of business in Hong Kong

Key Terms

Form 6-K, foreign private issuer, principal place of business, independent non-executive Directors

4 terms

Form 6-K regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

principal place of business financial

"the principal place of business of the Company in Hong Kong has been changed"

independent non-executive Directors financial

"Mr. Ye Changqing, Mr. Ren Wei and Dr. David Sidransky and Ms. Marina S. Bozilenko and Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors"

Independent non-executive directors are board members who do not work for the company and have no significant financial or personal ties to its managers; they do not run day-to-day operations but attend board meetings to oversee strategy and decisions. For investors, they matter because they act like outside referees or impartial advisors who help prevent self-dealing, challenge management when needed, and boost confidence that the company’s decisions serve shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ascentage Pharma Group International (AAPG) announce in this Form 6-K?

Ascentage Pharma Group International announces a change in its principal place of business in Hong Kong. The company reports that the new Hong Kong office address is Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong, effective April 1, 2026.

When did Ascentage Pharma Group International (AAPG) change its Hong Kong principal place of business?

The change of principal place of business in Hong Kong took effect on April 1, 2026. This effective date is specified in the company’s announcement, which is furnished as Exhibit 99.1 to the Form 6-K filed as a report of a foreign private issuer.

What is Ascentage Pharma Group International’s new Hong Kong office address?

Ascentage Pharma Group International’s new principal place of business in Hong Kong is Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong. The board of directors states that this change became effective on April 1, 2026, replacing the previous Hong Kong business address.

Which document contains details of Ascentage Pharma Group International’s address change?

Details of the address change are contained in an announcement titled “Change of Principal Place of Business in Hong Kong,” dated April 1, 2026. This announcement is furnished as Exhibit 99.1 to Ascentage Pharma Group International’s Form 6-K report filed as a foreign private issuer.

Who signed the Form 6-K for Ascentage Pharma Group International (AAPG)?

The Form 6-K was signed on behalf of Ascentage Pharma Group International by Dr. Dajun Yang. He is identified in the filing as the Chief Executive Officer, and also appears in the announcement as Chairman and Executive Director of the company’s board of directors.

How is the board of Ascentage Pharma Group International structured in this announcement?

The announcement notes that the board comprises Chairman and executive Director Dr. Yang Dajun, non-executive Directors Dr. Wang Shaomeng and Dr. Lu Simon Dazhong, and independent non-executive Directors including Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu, and Marc E. Lippman, MD.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of April 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

On April 1, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued an announcement entitled, “Change of Principal Place of Business in Hong Kong”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.

1

INDEX TO EXHIBITS

Exhibit Number		Exhibit Title
99.1		Announcement dated April 1, 2026

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: April 1, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

Exhibit 99.1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board (the “Board”) of directors (the “Directors”) of Ascentage Pharma Group International (the “Company”) announces that the principal place of business of the Company in Hong Kong has been changed to Unit 906, 9/F., Haleson Building, 1 Jubilee Street, Central, Hong Kong with effect from April 1, 2026.

By order of the Board

Ascentage Pharma Group International Dr. Yang

Dajun

Chairman and Executive Director

Suzhou, People’s Republic of China, April 1, 2026

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei and Dr. David SidranskyNote2 and Ms. Marina S. Bozilenko and Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.

Notes:

1. Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements.

2. Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 ANNOUNCEMENT DATED APRIL 1, 2026 6.2 KB